Houston, TX – September 18, 2019 – Pulmotect, Inc., a clinical-stage biotechnology company developing an inhaled immunomodulatory agent, is pleased to announce the appointment of Dr. Kumar Srinivasan to its Board of Directors. Srinivasan is currently Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca. His appointment will expand the Pulmotect Board to six members.
With a third clinical trial underway supporting the lead technology and following the recent Series B investment led by Fannin Innovation Studio in partnership with Jefferson River Capital, Srinivasan’s addition to the Board builds on Pulmotect’s development momentum. Pulmotect’s lead product, PUL-042, is an immunomodulatory agent that boosts the innate immune system to prevent and treat respiratory infections. A study evaluating virus-induced symptoms in subjects with COPD is actively enrolling in London, with expected completion later this year.
“Kumar’s broad industry experience across important key development activities will add a valuable perspective to our Board,” said Leo Linbeck III, Chairman. “We appreciate his willingness to serve as a director and look forward to benefitting from his experience, judgment, and counsel.”
“I am delighted to join the board of Pulmotect, and I look forward to working with the rest of the board and management to add value to the company,” commented Srinivasan.
Srinivasan brings to Pulmotect broad cross-functional experience in business development, licensing, R&D, new product planning, finance and strategy, and he is an effective leader of multidisciplinary teams. He joined AstraZeneca in April 2012 as Vice President, Business Development and was appointed Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D in September 2019.
Srinivasan was previously Chief Business Officer at Probiodrug AG, then a private venture-funded German company developing novel treatments for Alzheimer’s and inflammatory diseases. Before this, he was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he ran business development and licensing activities for pre-Phase 2 opportunities in several therapeutic areas.
Pulmotect is developing PUL-042, a clinical-stage, first-in-class, inhaled, immunomodulatory agent. A synergistic agonist that amplifies the innate immune defenses of the lung epithelial mucosa to provide broad-spectrum, pathogen-agnostic protection against respiratory infections. Invented at UT MD Anderson Cancer Center/Texas A&M University, PUL-042 has patents issued in 9 countries both as a stand-alone composition of matter product and in combination with antivirals. The company has raised over $28M to date.
For more information, visit www.pulmotect.com